Effects of moniliformin and selenium on human articular cartilage metabolism and their potential relationships to the pathogenesis of Kashin-Beck disease.
OBJECTIVE
To investigate the effects of mycotoxin moniliformin (MON) on the metabolism of aggrecan and type II collagen in human chondrocytes in vitro and the relationship between MON and Kashin-Beck disease (KBD).


METHODS
Human chondrocytes were isolated and cultured on bone matrix gelatin to form an artificial cartilage model in vitro with or without MON toxin. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The expression of aggrecan and type II collagen in the cartilage was determined using immunocytochemical staining.


RESULTS
MON toxin inhibited chondrocyte viability in dose-dependent and time-dependent manners. MON reduced aggrecan and type II collagen syntheses in the tissue-engineered cartilage. MON also increased the expression of matrix metalloproteinase-1 (MMP-1), MMP-13, BC4 epitopes, and CD44 in cartilages. However, the expression of 3B3(-) epitopes in cartilages was inhibited by MON. Selenium partially alleviated the damage of aggrecan induced by MON toxin.


CONCLUSIONS
MON toxin promoted the catabolism of aggrecan and type II collagen in human chondrocytes.
Zhang
An
A
Institute of Endemic Diseases, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China.
Cao
Jun-ling
JL
Yang
Bo
B
Chen
Jing-hong
JH
Zhang
Zeng-tie
ZT
Li
Si-yuan
SY
Fu
Qiang
Q
Hugnes
Clare E
CE
Caterson
Bruce
B
D002357:Cartilage Diseases / Q000139:chemically induced* / Q000378:metabolism; D002358:Cartilage, Articular / Q000187:drug effects* / Q000378:metabolism; D002478:Cells, Cultured; D019902:Chondrocytes / Q000187:drug effects* / Q000378:metabolism*; D003503:Cyclobutanes / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D005240:Feasibility Studies; D006801:Humans; D012643:Selenium / Q000008:administration & dosage*
D003503:Cyclobutanes; D016326:Extracellular Matrix Proteins; C008539:moniliformin; D012643:Selenium